Table 2 Tumor response and outcomes of the 92 patients
| CCRT (n = 25) | Chemotherapy (n = 67) | p-value | |
|---|---|---|---|
| Capecitabine plus cisplatin chemotherapy, total cycles (mean ± SD) | 5.6 ± 5.8 | 4.0 ± 3.2 | 0.082 |
| Tumor response (n = 90), n (%) | 0.365 | ||
| CR | 0 (0) | 0 (0) | |
| PR | 1 (4.0) | 3 (4.6) | |
| SD | 13 (52.0) | 24 (36.9) | |
| PD | 11 (44.0) | 38 (58.5) | |
| Disease-control rate (CR + PR + SD) | 14 (56.0) | 27 (41.5) | 0.217 |
| Median FU duration, months (IQR) | 7.4 (4.1 – 15.1) | 4.1 (2.3 – 8.3) | 0.044 |
| Median PFS, months (95% CI) | 4.3 (3.3 – 5.4) | 1.9 (1.3 – 2.4) | 0.001* |
| Median OS, months (95% CI) | 9.3 (7.6 – 11.0) | 6.2 (4.1 – 8.2) | 0.162* |